1910, the only AI-native biotech pioneering small and large molecule therapeutics discovery, today announced the publication of PEGASUS (TM), a multimodal AI model that achieves state-of-the-art ...

PEGASUS generates permeable macrocyclic peptides, offering new promise for a modality that can combine the properties of a biologic in a pill ...

Insamo Inc., founded in 2022 to combine machine-learning capabilities, high-throughput screening and genetic engineering to create orally administered membrane-permeable cyclic peptides across a range ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

CycPeptMPDB, a novel database—created by Tokyo Tech researchers—focused on the membrane permeability of cyclic peptides, could accelerate the development of drugs based on these promising compounds.

Orbis Medicines emerged from stealth Feb. 29 with $28 million in seed funding. The company is the latest launched to turn cyclic peptide molecules into orally available drugs that could replace ...

The Tat-SIRT5-CTM peptide specifically blocked the interaction of SIRT5 with ANXA1, led to SIRT5 degradation and thereby inhibiting SIRT5-mediated desuccinylation of ANXA1, which in turn alleviated ...

1910, the only AI-native biotech pioneering small and large molecule therapeutics discovery, today announced the publication of PEGASUS™, a multimodal AI model that achieves state-of-the-art accuracy ...

To understand the focus of startup Insamo Inc., one need look no further than its name, which co-founder and CEO Timothy Craven described as “portmanteau of ‘internally satisfied molecules,’” ...